German industrial production unexpectedly rose in May, suggesting companies rushed production before potentially much higher tariffs on exports to the US https://t.co/kqqglgsP7I ...

In 1946, Eisenhower said, "I hate war as only a soldier who has lived it can. Only as one who has seen its brutality, its futility, its stupidity." Possibly my hatred of war blinds me so that I cannot comprehend the arguments they aduce. But in my opinion, there's no such thing as a preventative war. Although the suggestions repeatedly made, none has yet explained how war prevents war.Worse than this, no one has been able to explain away the fact that war creates the conditions that beget war. And finally, ...

Seralutinib Partnership with Chiesi - Chiesi will provide a $160 million immediate development reimbursement to Gossamer[13] - Gossamer and Chiesi will split US profits 50/50, with mid-to-high teens royalties to Gossamer ex-US[13] - Regulatory milestones could reach up to $146 million, and sales milestones up to $180 million[13] - R&D costs will be split 50/50 worldwide, with Gossamer leading global development and US commercialization of PAH & PH-ILD[13] - Gossamer has a pro forma cash position of approximately $396 million[20, 38] Seralutinib in PAH - Seralutinib is in an ongoing registrational Phase 3 trial for PAH, with topline results expected in Q4 2025[13, 24, 26] - The PROSERA Phase 3 study is a double-blind, placebo-controlled trial with 175 patients per arm[26] - The US has approximately 30,000 to 50,000 PAH patients, with a 5-year survival rate of 57%[13, 22, 23, 35] Seralutinib in PH-ILD - The US has approximately 60,000 to 100,000 PH-ILD patients[13, 29, 35] - The median 5-year survival for PH-ILD patients is 23%[13, 35] - A Phase 3 study in PH-ILD is expected to begin in mid-2025[13, 20] - Only one therapy is approved for PH-ILD in the US[29, 30, 35]

New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to speed up the process. (Photo: Maria Ponce) https://t.co/wWD1GG2CwU https://t.co/OfdTG5b3B9 ...

June 30, 2025 03:21 PM GMT China Financials | Asia Pacific Tracking Industrial Risks: Will Weaker May Data Lead to Higher Risks? Key Takeaways Despite weaker May industrial profit growth, we believe the incremental impact on industrial credit risks remains small due to: 1) profit deterioration concentrated in a few sectors affected by US tariffs; 2) US tariffs have declined notably from the peak in April and early May; 3) negative impact on EBIT interest coverage remains modest. Positively, more sectors hav ...

New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to speed up the process. https://t.co/T6WH2fPZeM https://t.co/T6WH2fPZeM ...

London, United Kingdom--(Newsfile Corp. - July 3, 2025) - Gorilla Technology Group Inc. (NASDAQ: GRRR) ("Gorilla" or the "Company"), a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology, is pleased to invite investors to a webinar on July 10, 2025, at 8:30 a.m. ET. The exclusive event, hosted by RedChip Companies, will feature Gorilla's Chairman and CEO, Jay Chandan, who will discuss Gorilla's leadership in AI-based Industrial IoT and Security ...

Digital twins is quite a big hot topic at the moment. Is there an idea of making a kind of digital twin of yourself for healthcare purposes. Yeah, we see that a lot and it can mean different things for different people.For the pharma industry, for example, where there's a lot of work trying to see how far we can go with clinical trials, if we manage to assemble uh virtual cohorts that are allowing us to in the end gain as much knowledge about the safety and efficacy of a drug, but without needing as many pe ...

There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific issues that predate this year. Take, for instance, CRISPR Therapeutics (CRSP 6.43%) and Viking Therapeutics (VKTX 4.01%), two mid-cap biotech companies that have lagged broader equities over the trailing-12-month period.Even with these poor performances, however, there are solid reasons to consider investing in these stocks, especially at current levels. Read on to find out more. 1. CRIS ...

华润微688396 时间: 2025年7月3日星期四 60.41分综合得分 较强 趋势方向 主力成本分析 20日主力成本 47.63 元 当日主力成本 47.34 元 5日主力成本 46.31 元 46.53 元 60日主力成本 周期内涨跌停 过去一年内该股 涨停 1次 跌停 0 次 北向资金数据 44.87 中期支撑位 | 持股量1356.52万股 | 占流通比1.02% | | --- | --- | | 昨日净买入-18.00万股 | 昨日增仓比-0.014% | | 5日增仓比-0.119% | 20日增仓比-0.153% | 技术面分析 47.79 短期压力位 46.45 短期支撑位 47.79 中期压力位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 暂无特殊形态 资金流数据 2025年07月03日的资金流向数据方面 | 主力资金净流出105.58万元 | | --- | | 占总成交额-1% | | 超大单净流出1068.92万元 | | 大单净流入963.34万元 | | 散户资金净流入278.76万 | 关联行业/概念板块 半导体 0.3 ...